However, this study [92] using a quantitative PCR method showed that KLK14 gene expression was down-regulated in ovarian cancer specimens, compared with normal ovary or benign ovarian tumor tissues, and that its positivity in cancers was associated with better rates of PFS (HR = 0.53, 95% CI = 0.31–0.93, P = 0.027) and OS (HR = 0.42, 95% CI = 0.21–0.84, P = 0.014) even in a multivariate setting as well as enhanced sensitivity to chemotherapy. The gene discussed is KLK14; the disease is ovarian cancer.